Biomolecular therapeutics, by design

Our research spans the design and development of advanced biomolecular therapeutics with applications in cancer immunotherapy, vaccine development, and precision medicine. We integrate synthetic biology, biomaterials science, and immunoengineering to address key challenges in therapeutic delivery and immune modulation.

Engineering RNA-based circuits for tumor microenvironment modulation

Many tumors exist in environments that are immunosuppressive, limiting the body’s natural immune response to cancer. By applying synthetic biology approaches, we design RNA-based gene circuits that precisely control the balance of key signaling molecules in the tumor microenvironment. Through this strategy, we aim to shift the environment to a more inflammatory state, enhancing the immune system’s ability to detect and target cancer cells effectively. Our ultimate goal is to develop therapeutic strategies that modulate immune responses in a way that maximizes efficacy while minimizing adverse effects.

Developing controlled-release vaccines

In this area, we are working to create vaccines that mimic the natural immune response to infection through sustained antigen exposure. Traditional vaccine delivery often requires booster doses, which can be challenging for global distribution and adherence. By leveraging advanced biomaterial platforms, we aim to design vaccine formulations that provide prolonged antigen release from a single dose. This approach can enhance the immune response by extending antigen presence over time, leading to more durable immunity. Our research explores the use of engineered biopolymers to achieve controlled, depot-forming delivery of both vaccine antigens and adjuvants, with applications in infectious disease prevention and cancer immunotherapy.

Harnessing endogenous mechanisms for advanced therapeutics

Endogenous biological systems can interact with and modify biomolecular therapeutics and are often exploited by pathogens. Our research investigates these interactions to leverage the endogenous response mechanisms for developing precise and effective nucleic acid therapeutics. By bridging fundamental biology and therapeutic design, we aim to create next-generation therapies that synergize with the body’s natural processes.